Breast cancer · 28 regimens
Cost vs Efficacy · 14 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
T-DM1 and ET Variant #01 Partial | ER|ERBB2 | R 41 405 | 21d | — | — | ~4 | ~R 165 620 indirect | — |
Trastuzumab emtansine monotherapy Variant #01 | ER|ERBB2 | R 41 405 | 21d | ~7.4 mo | ~29.9 mo | ~4 | ~R 165 620 PFS proxy · indirect | 7 |
Carboplatin and nab-Paclitaxel (CnP) Variant #01 | TNBC | R 41 178 | 21d | ~5.7 mo | ~13.9 mo | ~4 | ~R 164 713 PFS proxy · indirect | 11 |
Docetaxel and Bevacizumab Variant #01 | TNBC | R 32 908 | 21d | ~8.2 mo | — | ~2 | ~R 65 815 PFS proxy · indirect | 4 |
Cyclophosphamide and Epirubicin (EC) and Bevacizumab Variant #01 | TNBC | R 32 416 | 21d | ~9.2 mo | — | ~8 | ~R 259 324 PFS proxy · indirect | 1 |
Cisplatin and Bevacizumab Variant #01 | TNBC | R 30 427 | 21d | — | — | ~4 | ~R 91 724 indirect | — |
Trastuzumab and ET Variant #01 Partial | ER|ERBB2 | R 14 059 | 21d | — | — | ~4 | ~R 23 431 indirect | — |
iddEPC Variant #01 | — | R 5 631 | 14d | — | — | ~3 | ~R 16 894 PFS proxy · indirect | 1 |
Carboplatin and Docetaxel (DCb) Variant #06 | TNBC | R 5 501 | 21d | ~4.7 mo | ~22.3 mo | ~6 | ~R 33 004 PFS proxy · indirect | 4 |
EDC Variant #01 | — | R 5 103 | 21d | — | — | ~6 | ~R 30 617 indirect | — |
DI EC Variant #01 | — | R 4 458 | 21d | — | — | ~4 | ~R 17 834 indirect | — |
Docetaxel and Epirubicin (DE) Variant #01 | — | R 4 064 | 21d | — | — | ~3 | ~R 12 193 indirect | — |
Capecitabine and Docetaxel (TX) Variant #01 | — | R 3 311 | 21d | ~8.4 mo | ~14.5 mo | ~2 | ~R 6 622 PFS proxy · indirect | 3 |
Epirubicin monotherapy Variant #01 | — | R 3 200 | 21d | ~8.2 mo | ~19.1 mo | ~7 | ~R 22 400 PFS proxy · indirect | 1 |
TAC (Docetaxel) Variant #01 | — | R 2 905 | 21d | — | — | ~4 | ~R 11 619 PFS proxy · indirect | 2 |
Dose-dense Docetaxel and Doxorubicin (ddAT) Variant #01 | — | R 2 779 | 14d | — | — | ~4 | ~R 11 118 indirect | — |
Epirubicin and Paclitaxel (EP) Variant #01 | — | R 2 715 | 21d | — | — | 4 | R 10 860 PFS proxy | 1 |
PET Variant #01 | — | R 2 345 | 7d | — | — | ~12 | ~R 28 134 indirect | — |
FEC Variant #01 | — | R 2 049 | 21d | — | — | 2 | R 4 097 PFS proxy | 1 |
FAC Variant #11 | — | R 1 076 | 21d | ~8.0 mo | ~17.3 mo | ~9 | ~R 9 685 PFS proxy · indirect | 4 |
Carboplatin and Paclitaxel (CP) Variant #02 | TNBC | R 1 025 | 21d | ~12.6 mo | ~28.2 mo | ~12 | ~R 12 296 PFS proxy · indirect | 2 |
Cyclophosphamide and Doxorubicin (AC) Variant #01 | — | R 864 | 21d | ~8.0 mo | ~20.3 mo | ~6 | ~R 5 185 PFS proxy · indirect | 2 |
Cyclophosphamide and Doxorubicin (AC) Variant #01 | TNBC | R 864 | 21d | ~8.0 mo | ~20.3 mo | ~6 | ~R 5 185 PFS proxy · indirect | 2 |
Dose-dense Cyclophosphamide and Doxorubicin (ddAC) Variant #01 | TNBC | R 770 | 14d | — | — | ~6 | ~R 4 621 PFS proxy · indirect | 1 |
Dose-dense Cyclophosphamide and Doxorubicin (ddAC) Variant #01 | — | R 770 | 14d | — | — | ~6 | ~R 4 621 PFS proxy · indirect | 1 |
Paclitaxel monotherapy Variant #02 | — | R 734 | 28d | ~6.4 mo | ~16.8 mo | ~6 | ~R 4 406 PFS proxy · indirect | 28 |
Paclitaxel monotherapy Variant #02 | TNBC | R 734 | 28d | ~6.4 mo | ~16.8 mo | ~6 | ~R 4 406 PFS proxy · indirect | 28 |
Cisplatin monotherapy Variant #01 | TNBC | R 588 | 21d | ~2.1 mo | ~8.7 mo | ~6 | ~R 3 530 PFS proxy · indirect | 8 |
28 of 28 regimens shown